Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Greenwich Lifesciences Inc (GLSI)

Greenwich Lifesciences Inc (GLSI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Greenwich LifeSciences Provides Update on FLAMINGO-01 Cash Burn Rate and Financing Strategy GlobeNewswire - Tue Jan 27, 5:00AM CST

STAFFORD, Texas, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,...

GLSI : 29.00 (+15.13%)
Greenwich LifeSciences Announces FDA Approves Use of Commercially Manufactured GP2 in FLAMINGO-01 GlobeNewswire - Thu Jan 22, 5:00AM CST

STAFFORD, Texas, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,...

GLSI : 29.00 (+15.13%)
The $69B Precision Pivot: Why Biomarker Platforms are Igniting a New Oncology Gold Rush BayStreet.ca - Wed Jan 14, 8:56AM CST

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The genomics in cancer care market is on a massive tear, projected to hit $69.16 billion by 2032 as doctors...

ONCY : 0.8859 (+5.89%)
BCT.TO : 5.70 (-0.52%)
ACRV : 1.6700 (+4.37%)
LLY : 1,058.18 (+3.66%)
BCTX : 4.18 (+0.24%)
GLSI : 29.00 (+15.13%)
CATX : 4.71 (+1.73%)
Greenwich LifeSciences Extends Lock-up of Directors and Officers to September 30, 2026 GlobeNewswire - Mon Dec 29, 2025

STAFFORD, Texas, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,...

GLSI : 29.00 (+15.13%)
Greenwich LifeSciences Provides Additional Updates on FLAMINGO-01 and Corporate Strategy GlobeNewswire - Mon Dec 22, 2025

STAFFORD, Texas, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,...

GLSI : 29.00 (+15.13%)
Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01 GlobeNewswire - Mon Dec 15, 2025

STAFFORD, Texas, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,...

GLSI : 29.00 (+15.13%)
Greenwich LifeSciences Announces Completion of Enrollment in the Open Label Arm of FLAMINGO-01  GlobeNewswire - Mon Dec 8, 2025

STAFFORD, Texas, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,...

GLSI : 29.00 (+15.13%)
Greenwich LifeSciences Provides Global Update on FLAMINGO-01, Screening Over 1,000 Patients to Date GlobeNewswire - Wed Dec 3, 2025

STAFFORD, Texas, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,...

GLSI : 29.00 (+15.13%)
Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Belgium GlobeNewswire - Thu Oct 2, 2025

STAFFORD, Texas, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,...

GLSI : 29.00 (+15.13%)
Greenwich LifeSciences Announces Addition of Portugal to Flamingo-01 Clinical Trial GlobeNewswire - Tue Sep 30, 2025

STAFFORD, Texas, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,...

GLSI : 29.00 (+15.13%)

Barchart Exclusives

These 3 Dividend Stocks Combine Income, Momentum, and Upside Barchart - Fri Feb 6, 6:00PM CST
Three dividend stocks with strong buy ratings, solid income today, and upside potential in 2026 based on Barchart strength and analyst consensus. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot